Presentation Type
Oral Presentation
Category
STEM (science, technology, engineering, mathematics)
Abstract/Artist Statement
Medication-assisted treatment (MAT) is an evidence-based approach for opioid use disorder (OUD) using medications like buprenorphine, methadone, and naltrexone to treat symptoms of OUD and withdrawal. Despite reducing opioid-related deaths by 50% and improving employment, criminal activity, and birth outcomes, its acceptance in Montana's substance use disorder (SUD) housing varies. Experts stress MAT as essential medical care, yet stigma-driven policies still restrict access, forcing some to choose between medication and treatment.
This study explores the landscape of MAT acceptance in Montana SUD treatment facilities, highlighting the barriers that prevent its widespread acceptance, differences regarding treatment duration, approved medications, and administration protocols.
Interviews with 15 facilities in MT revealed that 13 accept patients using MAT, although their approaches differ, with administration commonly outsourced to medical providers. Despite its proven benefits, MAT stigma and structural barriers continue to persist, particularly among abstinence-based programs that view MAT as merely replacing one substance with another.
Structural barriers further complicate MAT accessibility, as abstinence-based philosophies and rural geography exacerbate access issues. Counselors with personal recovery histories may resist integrating MAT practices, viewing it as incongruous with sobriety. 5 of the 15 facilities also require MAT medications to be administered offsite, posing logistical burdens for individuals in remote areas. Additionally, misconceptions within the broader healthcare community lead to discrimination against MAT patients, limiting their access to comprehensive care in Montana. These attitudes contribute to gaps in treatment availability, ultimately placing individuals with OUD at greater risk of relapse or overdose.
This study underscores the urgent need for education, policy reform, and community engagement to dismantle misconceptions about MAT in Montana. Addressing these barriers is critical to ensuring that individuals with OUD receive the life-saving treatment they need within an inclusive and supportive recovery system.
Mentor Name
Kari Harris
Medication-Assisted Treatment for Opioid Use Disorder in Montana: Barriers and Best Practices
UC 327
Medication-assisted treatment (MAT) is an evidence-based approach for opioid use disorder (OUD) using medications like buprenorphine, methadone, and naltrexone to treat symptoms of OUD and withdrawal. Despite reducing opioid-related deaths by 50% and improving employment, criminal activity, and birth outcomes, its acceptance in Montana's substance use disorder (SUD) housing varies. Experts stress MAT as essential medical care, yet stigma-driven policies still restrict access, forcing some to choose between medication and treatment.
This study explores the landscape of MAT acceptance in Montana SUD treatment facilities, highlighting the barriers that prevent its widespread acceptance, differences regarding treatment duration, approved medications, and administration protocols.
Interviews with 15 facilities in MT revealed that 13 accept patients using MAT, although their approaches differ, with administration commonly outsourced to medical providers. Despite its proven benefits, MAT stigma and structural barriers continue to persist, particularly among abstinence-based programs that view MAT as merely replacing one substance with another.
Structural barriers further complicate MAT accessibility, as abstinence-based philosophies and rural geography exacerbate access issues. Counselors with personal recovery histories may resist integrating MAT practices, viewing it as incongruous with sobriety. 5 of the 15 facilities also require MAT medications to be administered offsite, posing logistical burdens for individuals in remote areas. Additionally, misconceptions within the broader healthcare community lead to discrimination against MAT patients, limiting their access to comprehensive care in Montana. These attitudes contribute to gaps in treatment availability, ultimately placing individuals with OUD at greater risk of relapse or overdose.
This study underscores the urgent need for education, policy reform, and community engagement to dismantle misconceptions about MAT in Montana. Addressing these barriers is critical to ensuring that individuals with OUD receive the life-saving treatment they need within an inclusive and supportive recovery system.